PL3240801T3 - Skojarzona immunoterapia nowotworów - Google Patents

Skojarzona immunoterapia nowotworów

Info

Publication number
PL3240801T3
PL3240801T3 PL15876030T PL15876030T PL3240801T3 PL 3240801 T3 PL3240801 T3 PL 3240801T3 PL 15876030 T PL15876030 T PL 15876030T PL 15876030 T PL15876030 T PL 15876030T PL 3240801 T3 PL3240801 T3 PL 3240801T3
Authority
PL
Poland
Prior art keywords
tumor immunotherapy
combination tumor
combination
immunotherapy
tumor
Prior art date
Application number
PL15876030T
Other languages
English (en)
Polish (pl)
Inventor
Arthur M. Krieg
Original Assignee
Checkmate Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Checkmate Pharmaceuticals, Inc. filed Critical Checkmate Pharmaceuticals, Inc.
Publication of PL3240801T3 publication Critical patent/PL3240801T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL15876030T 2014-12-31 2015-12-22 Skojarzona immunoterapia nowotworów PL3240801T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462098568P 2014-12-31 2014-12-31
US201562106526P 2015-01-22 2015-01-22
US201562118165P 2015-02-19 2015-02-19
EP15876030.6A EP3240801B1 (en) 2014-12-31 2015-12-22 Combination tumor immunotherapy
PCT/US2015/067269 WO2016109310A1 (en) 2014-12-31 2015-12-22 Combination tumor immunotherapy

Publications (1)

Publication Number Publication Date
PL3240801T3 true PL3240801T3 (pl) 2021-06-14

Family

ID=56284932

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15876030T PL3240801T3 (pl) 2014-12-31 2015-12-22 Skojarzona immunoterapia nowotworów

Country Status (20)

Country Link
US (2) US10682365B2 (OSRAM)
EP (2) EP3240801B1 (OSRAM)
JP (2) JP6885867B2 (OSRAM)
CN (2) CN113813386A (OSRAM)
AU (2) AU2015374385B2 (OSRAM)
CY (1) CY1123868T1 (OSRAM)
DK (1) DK3240801T3 (OSRAM)
ES (1) ES2856844T3 (OSRAM)
HR (1) HRP20210200T1 (OSRAM)
HU (1) HUE053145T2 (OSRAM)
LT (1) LT3240801T (OSRAM)
MX (2) MX393750B (OSRAM)
NZ (2) NZ734144A (OSRAM)
PL (1) PL3240801T3 (OSRAM)
PT (1) PT3240801T (OSRAM)
RS (1) RS61470B1 (OSRAM)
SI (1) SI3240801T1 (OSRAM)
SM (1) SMT202100094T1 (OSRAM)
WO (1) WO2016109310A1 (OSRAM)
ZA (1) ZA202005298B (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200030375A1 (en) * 2012-06-27 2020-01-30 Kenichiro Hasumi Therapy and methods of introducing immature dendritic cells and/or cytoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
RS61470B1 (sr) * 2014-12-31 2021-03-31 Checkmate Pharmaceuticals Inc Kombinovana antitumorska imunoterapija
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
MA44699A (fr) * 2015-05-29 2021-05-05 Merck Sharp & Dohme Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
EP4218776A3 (en) 2015-08-06 2024-02-28 Regents of the University of Minnesota Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
EP3213768A1 (en) 2016-03-01 2017-09-06 LODOCO CLINICAL Kft Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer
US20190046638A1 (en) * 2016-04-01 2019-02-14 Checkmate Pharmaceuticals, Inc. Fc RECEPTOR-MEDIATED DRUG DELIVERY
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
EP3534950A4 (en) 2016-11-01 2020-05-06 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
CN110072553B (zh) * 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
MX2019008207A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-pd-1.
WO2018181542A1 (ja) * 2017-03-29 2018-10-04 テルモ株式会社 アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
WO2019160866A2 (en) * 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
AU2019251421B2 (en) 2018-04-09 2025-05-01 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
TW202011959A (zh) 2018-04-14 2020-04-01 美商戴納瓦克斯技術公司 用於治療癌症之包括CpG-C 型寡核苷酸及組蛋白去乙醯酶抑制劑之組合
CN108486120B (zh) * 2018-04-28 2019-12-06 新乡医学院 一种新型CpG ODN序列及其在抗黑色素瘤上的应用
EP3566718A1 (en) * 2018-05-07 2019-11-13 Universitätsmedizin der Johannes Gutenberg-Universität Mainz A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer
TWI831789B (zh) 2018-06-05 2024-02-11 大陸商江蘇康寧杰瑞生物製藥有限公司 二聚體及其用途
WO2020081398A1 (en) * 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
JP2022512745A (ja) * 2018-10-18 2022-02-07 アイデラ・ファーマシューティカルズ，インコーポレーテッド がんを処置するためのｔｌｒ９調節因子
US12179037B2 (en) 2018-12-11 2024-12-31 Board Of Regents, The University Of Texas System Radiotherapies and uses thereof
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
US11613755B2 (en) 2019-12-31 2023-03-28 Industrial Technology Research Institute Nucleic acid-drug complex and use thereof
WO2021231741A2 (en) * 2020-05-14 2021-11-18 Elixiron Immunotherapeutics (hong Kong) Limited Anti-pd-l1 antibodies and anti-pd-l1/il10 fusion proteins
WO2022110010A1 (zh) * 2020-11-27 2022-06-02 苏州吉玛基因股份有限公司 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用
CN114099535B (zh) * 2020-12-10 2023-01-03 南京吉迈生物技术有限公司 Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物
KR20240004419A (ko) * 2021-04-01 2024-01-11 트라이살루스 라이프 사이언시즈, 인크. 톨-유사 수용체 작용제를 사용한 암 요법
US11898147B2 (en) * 2021-09-06 2024-02-13 National Health Research Institutes CpG-oligodeoxynucleotide compounds in combination with immune modulators for cancer immunotherapy
WO2023096934A1 (en) * 2021-11-24 2023-06-01 Wisconsin Alumni Research Foundation Nanoparticles for potentiating effects of radiation therapy on anti-cancer immunotherapy
CN118679266A (zh) 2022-01-03 2024-09-20 查克美特制药公司 对先天免疫激活剂的反应的转录生物标志物
CN114982711B (zh) * 2022-05-30 2023-11-10 广东省人民医院 小鼠胃间质瘤自发成瘤模型及其构建方法和应用
WO2025117535A1 (en) * 2023-11-29 2025-06-05 Zola Therapeutics Inc. Synthetic immunostimulatory nucleic acids for immunotherapy of cancer and other diseases

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
AU568067B2 (en) 1981-10-23 1987-12-17 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5859231A (en) 1993-09-03 1999-01-12 Duke University Synthesis of oligonucleotides with boranophosphonate linkages
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US20020088014A1 (en) 1996-05-31 2002-07-04 Xiangming Fang Minimal adenovirus mediated recombinant vaccine
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
DE19826758C1 (de) 1998-06-15 1999-10-21 Soft Gene Gmbh Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte
AU764532B2 (en) 1998-07-27 2003-08-21 University Of Iowa Research Foundation, The Stereoisomers of CpG oligonucleotides and related methods
CN1346369B (zh) 1998-10-23 2011-09-28 安姆根有限公司 用于预防和治疗贫血的方法以及组合物
JP5341287B2 (ja) 1998-12-03 2013-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｃｔｌａ−４遮断薬を用いる自己抗原に対するｔ細胞の刺激
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
JP5022551B2 (ja) 2000-04-21 2012-09-12 アムジエン・インコーポレーテツド 貧血の予防及び治療用の方法及び組成物
ATE374214T1 (de) 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
NZ552377A (en) 2001-08-17 2008-08-29 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
MXPA05009289A (es) 2003-03-26 2005-10-18 Cytos Biotechnology Ag Conjugados de particulas tipo virus del analogo del peptido melan-a.
RU2354694C2 (ru) 2003-12-30 2009-05-10 Мологен Аг Аллогенное противоопухолевое терапевтическое средство
DK1716234T3 (da) 2004-02-20 2014-01-20 Mologen Ag Substitueret, ikke-kodende nukleinsyremolekyle til terapeutisk og profylaktisk immunstimulering i mennesker og højerestående dyr
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EA200800268A1 (ru) 2005-07-07 2008-06-30 Коли Фармасьютикал Груп, Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
BRPI0618473A2 (pt) 2005-11-11 2011-08-30 Pfizer combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador
RU2451523C2 (ru) 2005-12-14 2012-05-27 Цитос Биотехнологи Аг Упакованные иммуностимулирующей нуклеиновой кислотой частицы, предназначенные для лечения гиперчувствительности
DK1991678T4 (da) 2006-02-15 2020-10-19 Rechtsanwalt Thomas Beck Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
EP2589654A1 (en) * 2006-05-03 2013-05-08 The Regents of the University of Colorado, a body corporate CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
JP5437797B2 (ja) 2006-06-12 2014-03-12 サイトス バイオテクノロジー アーゲー Ｒｎａバクテリオファージのウイルス様粒子にオリゴヌクレオチドをパッケージ化するための方法
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
CN101611048B (zh) 2006-12-12 2012-11-07 赛托斯生物技术公司 含有高浓度鸟嘌呤单体的寡核苷酸
WO2009022215A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
SG11201406592QA (en) * 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
RS61470B1 (sr) * 2014-12-31 2021-03-31 Checkmate Pharmaceuticals Inc Kombinovana antitumorska imunoterapija
MA44699A (fr) * 2015-05-29 2021-05-05 Merck Sharp & Dohme Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
US9917100B2 (en) 2015-11-20 2018-03-13 Sandisk Technologies Llc Three-dimensional NAND device containing support pedestal structures for a buried source line and method of making the same
ITUA20162720A1 (it) 2016-04-19 2017-10-19 Risco Spa Apparecchiatura per preparare un prodotto alimentare

Also Published As

Publication number Publication date
AU2015374385A1 (en) 2017-08-17
LT3240801T (lt) 2021-02-25
RS61470B1 (sr) 2021-03-31
CN107428813B (zh) 2021-08-03
ZA202005298B (en) 2022-02-23
MX2017008658A (es) 2018-02-23
EP3835312A1 (en) 2021-06-16
CA2972757A1 (en) 2016-07-07
EP3240801B1 (en) 2021-01-20
SI3240801T1 (sl) 2021-04-30
US10682365B2 (en) 2020-06-16
JP2021014465A (ja) 2021-02-12
ES2856844T3 (es) 2021-09-28
AU2020223671C1 (en) 2024-04-18
WO2016109310A1 (en) 2016-07-07
US20180000851A1 (en) 2018-01-04
US20200281953A1 (en) 2020-09-10
PT3240801T (pt) 2021-02-18
AU2015374385B2 (en) 2020-08-06
EP3240801A4 (en) 2018-07-25
DK3240801T3 (da) 2021-02-08
MX393750B (es) 2025-03-24
MX2022008338A (es) 2022-08-04
JP2018502120A (ja) 2018-01-25
CN107428813A (zh) 2017-12-01
NZ734144A (en) 2023-06-30
AU2020223671B2 (en) 2023-08-03
EP3240801A1 (en) 2017-11-08
HUE053145T2 (hu) 2021-06-28
CY1123868T1 (el) 2022-05-27
HK1246319A1 (en) 2018-09-07
NZ771297A (en) 2024-11-29
SMT202100094T1 (it) 2021-03-15
JP6885867B2 (ja) 2021-06-16
CN113813386A (zh) 2021-12-21
AU2020223671A1 (en) 2020-09-10
HRP20210200T1 (hr) 2021-04-02

Similar Documents

Publication Publication Date Title
ZA202005298B (en) Combination tumor immunotherapy
IL304663A (en) combination
GB201517022D0 (en) No details
IL247073A0 (en) combination
GB201410907D0 (en) No details
GB201519531D0 (en) No details
GB201517404D0 (en) No details
PT3107573T (pt) Imunoterapia com il-12 visada ao cancro
GB201418217D0 (en) No details
EP3215182A4 (en) Combination immunotherapy
GB201418216D0 (en) No details
GB201516796D0 (en) No details
GB201517412D0 (en) No details
GB201517574D0 (en) No details
PL3094345T3 (pl) Immunoterapia oparta na liposomach
LT3237349T (lt) Patobulintas biologinis rišiklis
SG11201703801SA (en) Novel methods
GB201508480D0 (en) Cancer
GB201517605D0 (en) No details
GB201410910D0 (en) No details
GB201402083D0 (en) Retaining means
GB201414542D0 (en) Novel therapy
GB201801971D0 (en) No details
GB201604703D0 (en) NO details
GB201604704D0 (en) No details